<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02454478</url>
  </required_header>
  <id_info>
    <org_study_id>E7080-J081-112</org_study_id>
    <nct_id>NCT02454478</nct_id>
  </id_info>
  <brief_title>Study of Lenvatinib in Combination With Everolimus in Patients With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)</brief_title>
  <official_title>Phase 1 Study of Lenvatinib in Combination With Everolimus in Patients With Unresectable Advanced or Metastatic RCC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1 study to investigate the tolerability and safety of lenvatinib in combination with
      Everolimus in participants with unresectable advanced or metastatic RCC.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">April 10, 2015</start_date>
  <completion_date type="Actual">May 31, 2017</completion_date>
  <primary_completion_date type="Actual">May 31, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events (AEs) and serious adverse events (SAEs) as a measure of tolerability and safety of lenvatinib in combination with everolimus</measure>
    <time_frame>For each participant, from the first patient first dose till 30 days after the last dose</time_frame>
    <description>Safety assessment will consist of monitoring and recording all AEs and SAEs: periodic laboratory test value, vital signs, 12-lead ECGs, echocardiograms or multiple gated acquisition scan (MUGA) including left ventricular ejection fraction (LVEF), Eastern Cooperative Oncology Group (ECOG) Performance Status (PS), physical examination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose limiting toxicity (DLT) of lenvatinib and everolimus</measure>
    <time_frame>Up to Cycle 1 (28 Days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum plasma concentration)</measure>
    <time_frame>Cycle 1 Day 1 and Cycle 1 Day 15 (Samples collected at predose, 1,2,4,8, and 24 (predose on the following day) hours postdose)</time_frame>
    <description>Plasma concentrations of lenvatinib and whole-blood concentration of everolimus will be calculated to determine the pharmacokinetic (PK) parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax (Time to achieve maximum concentration (Cmax))</measure>
    <time_frame>Cycle 1 Day 1 and Cycle 1 Day 15 (Samples collected at predose, 1,2,4,8, and 24 (predose on the following day) hours postdose)</time_frame>
    <description>Plasma concentrations of lenvatinib and whole-blood concentration of everolimus will be calculated to determine the PK parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration (AUC)</measure>
    <time_frame>Cycle 1 Day 1 and Cycle 1 Day 15 (Samples collected at predose, 1,2,4,8, and 24 (predose on the following day) hours postdose)</time_frame>
    <description>Plasma concentrations of lenvatinib and whole-blood concentration of everolimus will be calculated to determine the PK parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response (BOR)</measure>
    <time_frame>From date of first administration of study drug until disease progression, development of unacceptable toxicity, subject requests to discontinue, withdrawal of consent or up to approximately 2.5 years</time_frame>
    <description>Tumor assessment will be performed by investigator using RECIST 1.1 at screening, every 8 weeks after start of the study treatment, and as clinically indicated.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Carcinoma, Renal Cell</condition>
  <arm_group>
    <arm_group_label>Lenvatinib plus Everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib</intervention_name>
    <arm_group_label>Lenvatinib plus Everolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <arm_group_label>Lenvatinib plus Everolimus</arm_group_label>
    <other_name>Lenvatinib plus Everolimus orally once a day</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Voluntary agreement to provide written informed consent of this study

          2. Willing and able to comply with all aspects of the protocol after being fully informed
             of the content

          3. Males or females aged greater than or equal to 20 years at the time of informed
             consent

          4. Histological or cytological confirmation of RCC

          5. Participants must have confirmed diagnosis of unresectable advanced and/or metastatic
             RCC

          6. Disease progression following VEGF targeted therapy

          7. ECOG-PS of 0 to 1

          8. Adequately controlled blood pressure with or without the use of antihypertensive
             agents

          9. Participants with adequate function of major organs

         10. Adequate blood coagulation function, defined as international normalized ratio (INR)
             less than or equal to 1.5

         11. Survival expectation of 3 months or longer after study enrollment

         12. Participants with adequate washout period from the end of prior treatment to the start
             of study drug administration

         13. Females of childbearing potential must not have had unprotected sexual intercourse
             within 28 days before participant registration and must agree to use a highly
             effective method of contraception throughout the entire study period and for 30 days
             after final administration of investigational drug. If currently abstinent, the
             participant must agree to use a double-barrier method as described above if she
             becomes sexually active during this study period or for 30 days after investigational
             drug discontinuation. Females who are using hormonal contraceptives must have been on
             a stable dose of the same hormonal contraceptive product for at least 4 weeks before
             administration and must continue to use the same contraceptive during this study and
             for 30 days after investigational drug discontinuation.

         14. Male participants and their female partners must meet the criteria above

        Exclusion Criteria:

          1. Participants with CNS metastases are not eligible, unless they have completed local
             therapy and have discontinued the use of corticosteroids for this indication for at
             least 4 weeks before starting treatment in this study. Any signs (eg, radiologic) or
             symptoms of brain metastases must be stable for at least 4 weeks before starting study
             treatment.

          2. Prior exposure to lenvatinib

          3. Participants who have not recovered from toxicities to less than or equal to Grade 1
             as a result of prior anticancer therapy, except alopecia

          4. Major surgery within 3 weeks prior to the first dose of lenvatinib

          5. Participants with a urine protein greater than or equal to 1g/24 hours

          6. Uncontrollable diabetes as defined by fasting glucose greater than 1.5 X ULN

          7. Fasting total cholesterol greater than 7.75 mmol/L (greater than 300 mg/dL)

          8. Fasting triglycerides greater than 2.5 X ULN

          9. Any condition that might affect the absorption of lenvatinib and/or everolimus

         10. Significant cardiovascular impairment

         11. Bleeding or thrombotic disorders or use of anticoagulants requiring therapeutic INR
             monitoring

         12. Active hemoptysis

         13. Active infections that require systemic treatment

         14. Human immunodeficiency virus (HIV) positive

         15. Hepatitis B virus (HBV)

         16. A history of interstitial pneumonia with clinical manifestation or as confirmed by
             means of diagnostic imaging

         17. Medical need for the continued use of potent or moderate inhibitors of CYP3A or P-gp,
             or potent or moderate inducer of CYP3A

         18. Known intolerance to lenvatinib (or any of the excipients) or known hypersensitivity
             to everolimus (or any of the excipients) or rapmycins (sirolimus, temsirolimus and so
             on)

         19. Alcohol or drug dependency or abuse, inability to comply with every aspects of the
             study protocol, or any physical or mental conditions that in the opinion of the
             investigators would preclude the participant's participation in the study

         20. Females who are pregnant or breastfeeding (not eligible even she discontinues
             breastfeeding)

         21. Any medical or other condition which, in the opinion of the investigator, would
             preclude participation in a clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #2</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2015</study_first_submitted>
  <study_first_submitted_qc>May 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2015</study_first_posted>
  <last_update_submitted>March 15, 2018</last_update_submitted>
  <last_update_submitted_qc>March 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lenvatinib</keyword>
  <keyword>Everolimus</keyword>
  <keyword>Carcinoma</keyword>
  <keyword>Unresectable advanced renal cell carcinoma</keyword>
  <keyword>Metastatic renal cell carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenvatinib</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

